Overview

Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis

Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics (PD), immunogenicity, and efficacy of subcutaneous (SC) ALXN1830 in adults with generalized myasthenia gravis (gMG).
Phase:
Phase 2
Details
Lead Sponsor:
Alexion Pharmaceuticals